Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia

被引：0
|
作者：
Jie Sun [1 ]
Juan Hu [1 ]
Yan Huang [1 ]
Shuang-Wei Ying [1 ]
Xiao-Yan Han [1 ]
Yan-Long Zheng [1 ]
He Huang [1 ]
机构：
[1] Bone Marrow Transplantation Centre,The First Affiliated Hospital of Zhejiang University
来源：
中华医学杂志英文版 | 2016年 / 129卷 / 20期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R581.4 [甲状腺炎]; R733.7 [白血病];
学科分类号：
1002 ; 100201 ; 100214 ;
摘要：
To the Editor:Sorafenib is a novel,orally available inhibitor of multiple kinases.It has been used in relapsed and refractory FMS-like tyrosine kinase（FLT） -3-positive acute myeloid leukemia（AML） in recent years with favorable outcomes.Thyroiditis and hypothyroidism as side effects have been reported in treatment on renal cell cancer.;Here,we report a case of FLT3-internal tandem duplication（ITD） -positive AML,who developed subacute thyroiditis during treatment with sorafenib.
引用
收藏
页码：2512 / 2513
页数：2
相关论文
共 50 条
  • [21] Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement
    Suga, Makiko
    Fukushima, Kentaro
    Ueda, Tomoaki
    Arai, Yasuyuki
    Nakagawa, Shunsaku
    Minami, Yosuke
    Toda, Jun
    Hino, Akihisa
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    CLINICAL CASE REPORTS, 2022, 10 (02):
  • [22] INTERNAL TANDEM DUPLICATION OF FMS-LIKE TYROSINE KINASE-3 DETERMINES A SIGNIFICANT PROGNOSTIC FACTOR ON ACUTE PROMYELOCYTIC LEUKEMIA
    Tashiro, H.
    Oka, Y.
    Shirasaki, R.
    Sugao, T.
    Mizutani-Noguchi, M.
    Akiyama, N.
    Kawasugi, K.
    Shirafuji, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 510 - 510
  • [23] Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
    Xuan, Li
    Wang, Yu
    Chen, Jia
    Jiang, Erlie
    Gao, Li
    Wu, Bingyi
    Deng, Lan
    Liang, Xinquan
    Huang, Fen
    Fan, Zhiping
    Tang, Xiaowen
    Sun, Jing
    Zhang, Xi
    Han, Mingzhe
    Wu, Depei
    Huang, Xiaojun
    Liu, Qifa
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (08) : 1674 - 1681
  • [24] FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
    Novatcheva, Elli D.
    Anouty, Yasmine
    Saunders, Ila
    Mangan, James K.
    Goodman, Aaron M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E161 - E184
  • [25] FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia
    Parcells, Bertrand W.
    Ikeda, Alan K.
    Simms-Waldrip, Tiffany
    Moore, Theodore B.
    Sakamoto, Kathleen M.
    STEM CELLS, 2006, 24 (05) : 1174 - 1184
  • [26] FMS-like Tyrosine Kinase 3-Internal Tandem Duplication Allele Concentrations Should Be Determined in a Mutation-Type-Specific Manner
    Kim, Man Jin
    Shin, Ho Seob
    Oh, Hyeon Sae
    Cho, Sung Im
    Kim, Young-Gon
    Lee, Jee-Soo
    Park, Sung Sup
    Seong, Moon-Woo
    CLINICAL CHEMISTRY, 2021, 67 (04) : 691 - 693
  • [27] FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication and the Patterns of Its Gene Sequence in 207 Chinese Patients With De Novo Acute Myeloid Leukemia
    Zhong, Ling
    Jia, Yong Qian
    Meng, Wen Tong
    Ni, Xun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (01) : 84 - 89
  • [28] Efficacy and feasibility of sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 mutated acute myeloid leukemia
    Battipaglia, G.
    Ruggeri, A.
    Jestin, M.
    Massoud, R.
    El Cheikh, J.
    Antar, A.
    Ramdane, B.
    Brissot, E.
    Dulery, R.
    Eder, S.
    Giannotti, F.
    Isnard, F.
    Lapusan, S.
    Rubio, M. -T.
    Vekhoff, A.
    Legrand, O.
    Mohty, M.
    Bazarbachi, A.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S247 - S247
  • [29] Multiple Concurrent FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications (FLT3-ITDs) Do Not Impact Clinical Outcome in Acute Myeloid Leukemia (AML) Patients
    Fang, Hong
    Howard, Matthew T.
    Chen, Dong
    He, Rong
    Viswanatha, David S.
    LABORATORY INVESTIGATION, 2017, 97 : 348A - 348A
  • [30] Multiple Concurrent FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications (FLT3-ITDs) Do Not Impact Clinical Outcome in Acute Myeloid Leukemia (AML) Patients
    Fang, Hong
    Howard, Matthew T.
    Chen, Dong
    He, Rong
    Viswanatha, David S.
    MODERN PATHOLOGY, 2017, 30 : 348A - 348A
12345